Molecular Tumor Board: 68-year-old female with invasive ductal carcinoma of the right breast

In this molecular tumor board discussion, our Medical Affairs team reviews a case of de novo metastatic breast cancer where they emphasize the importance of comprehensive biomarker assessment, including hormone receptor and HER2 biomarkers in guiding therapeutic strategy. Additionally, the discussion highlights the growing role of liquid biopsy in identifying resistance mechanisms and optimizing treatment selection in advanced metastatic breast cancer.